Based on the Pfizer Limited stock forecast from 1 analysts, the average analyst target price for Pfizer Limited is INR 4,125.00 over the next 12 months. Pfizer Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pfizer Limited is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Pfizer Limited’s stock price was INR 4,148.70. Pfizer Limited’s stock price has changed by +0.83% over the past week, -4.60% over the past month and +10.07% over the last year.
No recent analyst target price found for Pfizer Limited
No recent average analyst rating found for Pfizer Limited
Company Overview Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, respiratory, and vitamins/minerals/nutrients. It sells its products through a network of independent distributors primarily under various brand names. The company was incorporated in 1950 and is headquartered in Mumbai, India. Read Less
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infect...Read More
Frequently Asked Questions About Pfizer Limited (PFIZER:NSE) Stock
Based on ratings from 1 analysts Pfizer Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
PFIZER:NSE stock's dividend yield is 2.38%.
Our analysis grades PFIZER:NSE stock's dividend yield at A+. This means that PFIZER:NSE stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this PFIZER:NSE may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for PFIZER:NSE is INR 4,125.00 over the next 12 months. The maximum analyst target price is INR 4125 while the minimum anlayst target price is INR 4125.
PFIZER:NSE stock's Price/Earning ratio is 38.23.
Our analysis grades PFIZER:NSE stock's Price / Earning ratio at F. This means that PFIZER:NSE stock's Price/Earning ratio is above 55.00000000000001% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this PFIZER:NSE may be a overvalued for its sector.
The last closing price of PFIZER:NSE's stock was INR 4,148.70.
The most recent market capitalization for PFIZER:NSE is INR 191.91B.
Based on targets from 1 analysts, the average taret price for PFIZER:NSE is projected at INR 4,125.00 over the next 12 months.
This means that PFIZER:NSE's stock price may go down by -0.57% over the next 12 months.
We can't find any ETFs which contains Pfizer Limited's stock.
As per our most recent records Pfizer Limited has 1,702 Employees.
Pfizer Limited's registered address is The Capital, Mumbai, India, 400051.
You can get more information about it from Pfizer Limited's website at https://www.pfizerltd.co.in.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PFIZER:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
